Riskpilot← Back to searchSign inGet full accessUNIKUM Therapeutics ApS
APSActiveCVR 41192925Kanehaven 33Research and experimental development on natural sciences and engineering · NACE 7210Est. 20202 employees
Revenue 2025
DKK -248K
-97% vs 2024
EBITDA margin
146.0%
+98% vs 2024
Equity ratio
-4119.0%
Financial strength
Net profit 2025
DKK -859K
+94% vs 2024
| Revenue | DKK -248K | -97% |
| EBITDA | DKK -362K | +98% |
| Net profit | DKK -859K | +94% |
| Total assets | DKK 138K | -96% |
| Equity | DKK -5,7M | -18% |
| Employees | 2 | — |
Legal name
UNIKUM Therapeutics ApS
CVR number
41192925
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
17. februar 2020
Share capital
DKK 89.038
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens formand i forening med et bestyrelsesmedlem eller en direktør
eller af den samlede bestyrelse.
Company purpose
Selskabets formål er forskning, udvikling og kommercialisering af lægemidler og hermed forbundet virksomhed.
Address
Kanehaven 33
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | -2.726 | -3.315 | -7.465 | -7.368 | -248 |
| Staff expenses | -3.685 | -4.853 | -7.895 | -7.888 | -114 |
| EBITDA | -6.411 | -8.168 | -15.361 | -15.257 | -362 |
| Depreciation & amort. | -16 | -16 | -14 | -0 | -0 |
| EBIT | -6.427 | -8.184 | -15.375 | -15.257 | -362 |
| Net financials | -601 | -719 | -1.351 | -657 | -534 |
| Profit before tax | -7.028 | -8.903 | -16.726 | -15.914 | -895 |
| Tax | -1.473 | -1.255 | -1.855 | -2.117 | -36 |
| Net profit | -5.555 | -7.649 | -14.871 | -13.797 | -859 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 6.700 | 3.057 | 3.996 | 3.759 | 138 |
| Equity | -7.645 | -15.294 | -16.284 | -4.821 | -5.680 |
| Long-term debt | 13.600 | 17.282 | 18.555 | 4.040 | 5.507 |
| Short-term debt | 745 | 1.069 | 1.726 | 4.540 | 311 |
| Total debt | 14.345 | 18.351 | 20.280 | 8.580 | 5.818 |
EBITDA margin
-36196600.0%
This company
15.8%
Market median
-229092505% vs market
20212025
Equity ratio
-4119.0%
This company
38.2%
Market median
-10883% vs market
20212025
Return on equity
-85907600.0%
This company
18.4%
Market median
-466889230% vs market
20212025
Net profit margin
-85907600.0%
This company
8.1%
Market median
-1060587754% vs market
20212025
Asset turnover
-1.80×
This company
1.12×
Market median
-261% vs market
20212025
Debt / equity
1.02×
This company
0.62×
Market median
-65% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MR Management | Management | 2024 |
| Former (3) | ||
TP Management | Management | 2023 – 2024 |
SS Management | Management | 2020 – 2021 |
RO Chief Executive Officer | Chief Executive Officer | 2023 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2024 | |
| Chairman | 2020 | |
| Former (3) | ||
| Board of Directors | 2023 – 2025 | |
| Board of Directors | 2023 – 2025 | |
| Board of Directors | 2023 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 33.33–49.99% | 33.33–49.99% | 2024 | |
| Company | 15–19.99% | 15–19.99% | 2024 | |
| Company | 5–9.99% | 5–9.99% | 2024 | |
| Company | 5–9.99% | 5–9.99% | 2023 | |
| Company | 5–9.99% | 5–9.99% | 2023 | |
| Company | 5–9.99% | 5–9.99% | 2024 | |
| Company | 5–9.99% | 5–9.99% | 2023 | |
| Company | 5–9.99% | 5–9.99% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
MEDIC ADVICE ApS
UNIKUM Therapeutics ApS Board members of UNIKUM Therapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tommi Petteri Kainu | Management | 0 companies |
| Søren Sylvester Skjærbæk | Management | 0 companies |
| Rasmus Otkjær Bak | Chief Executive Officer | 0 companies |
| Martin Roelsgaard Jakobsen | Management | 0 companies |
| Margo Rosemary Roberts | Board of Directors | 0 companies |
| Stefan Wildt | Board of Directors | 0 companies |
| Nebojsa Milovic | Board of Directors | 0 companies |
| Ulrik Bjerl Nielsen | Chairman | 0 companies |
| Johannes Heinrich Frühauf | Board of Directors | 0 companies |